SCHEMBL5373052

SCHEMBL5373052

CCc1cc(CO)ccc1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.63
ESR1 P03372 3/20 0.52
ESR2 Q92731 3/20 0.52
HSD17B1 P14061 2/20 0.50
PKM P14618 1/20 0.50
TRPA1 O75762 1/20 0.50
GABRA1 P14867 1/20 0.47
GABRB2 P47870 1/20 0.47
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
KLF10 Q13118 1/20 0.42
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1021944 0.86 BACE1 (0.68) BACE1ESR1ESR2HSD17B1PKM
SCHEMBL923601 0.84 BACE1 (0.66) BACE1ESR1ESR2HSD17B1TRPA1
SCHEMBL1604304 0.84 PKM (0.55) BACE1PKMGABRA1GABRB2KLF10
SCHEMBL29942487 0.84 PKM (0.55) BACE1PKMGABRA1GABRB2KLF10
SCHEMBL5372926 0.83 ALOX5 (0.57) BACE1ESR1ESR2PKMTRPA1
SCHEMBL8495480 0.83 TRPA1 (0.61) BACE1ESR1ESR2HSD17B1PKM
SCHEMBL28137809 0.83 TRPA1 (0.50) BACE1ESR1ESR2TRPA1HSP90AA1
Hydrochloric Acid SCHEMBL29565629 0.82 PKM (0.53) BACE1PKMGABRA1GABRB2KLF10
SCHEMBL606892 0.82 EGFR (0.43) BACE1PKMTRPA1GABRA1GABRB2
SCHEMBL1022604 0.81 BACE1 (0.72) BACE1ESR1ESR2HSD17B1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522569-B2 Substituted benzimidazole derivative and use thereof CHENGDU FANXI BIOPHARMA CO., LTD. (CN) 2026-01-13 US disclosed
CN-113912547-B Substituted benzene imidazole derivative and application thereof 成都凡诺西生物医药科技有限公司 2024-04-30 CN disclosed
US-20240026390-A1 CULTURE COMPOSITIONS AND METHODS OF THEIR USE FOR HIGH YIELD PRODUCTION OF VANILLIN EUAGORE, LLC 2024-01-25 US disclosed
US-20230227412-A1 Substituted Benzimidazole Derivative And Use Thereof CHENGDU FANXI BIOPHARMA CO., LTD. (CN) 2023-07-20 US disclosed
US-20230227412-A1 Substituted Benzimidazole Derivative And Use Thereof CHENGDU FANXI BIOPHARMA CO., LTD. (CN) 2023-07-20 US disclosed
US-20230227412-A1 Substituted Benzimidazole Derivative And Use Thereof CHENGDU FANXI BIOPHARMA CO., LTD. (CN) 2023-07-20 US disclosed
WO-2023132229-A1 ADHESIVE AGENT COMPOSITION, LAMINATE, METHOD FOR MANUFACTURING LAMINATE, AND METHOD FOR MANUFACTURING PROCESSED SUBSTRATE 日産化学株式会社 2023-07-13 WO disclosed
EP-4186891-A1 SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND USE THEREOF Chengdu Fanxi Biopharma Co., Ltd. (CN) 2023-05-31 EP disclosed
EP-4186891-A1 SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND USE THEREOF Chengdu Fanxi Biopharma Co., Ltd. (CN) 2023-05-31 EP disclosed
CN-113912547-A Substituted benzimidazole derivative and application thereof 成都凡诺西生物医药科技有限公司 2022-01-11 CN disclosed
US-5391566-A An endothelin antagonist, hypotensive agents, antiinflammatory agents for treating cardiovascular disorders, kidney disorders , brain disorders, asthma MERCK & CO., INC. (US) 1995-02-21 US disclosed
WO-1995003044-A1 BENZIMIDAZOLINONES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES MERCK & CO., INC. (US) 1995-02-02 WO disclosed
US-5264439-A Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element MERCK & CO., INC. (US) 1993-11-23 US disclosed
US-5246944-A Hypotensive and anxiolytic agents; antidepressants MERCK & CO., INC. (US) 1993-09-21 US disclosed
US-5240938-A Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring MERCK & CO., INC. (US) 1993-08-31 US disclosed
EP-0527534-A1 Quinoline and azaquinoline angiotensin II antagonists MERCK & CO. INC. (US) 1993-02-17 EP disclosed
US-5183810-A Hyptoensive agents MERCK & CO., INC. (US) 1993-02-02 US disclosed
EP-0515535-A1 ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT MERCK & CO. INC. (US) 1992-12-02 EP disclosed
WO-1991012001-A1 ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT MERCK & CO., INC. (US) 1991-08-22 WO disclosed
US-4119671-A OXIDATION OF HYDROXYBENZYL ALCOHOLS, PLATINUM CATALYST, ACTIVATORS BAYER AKTIENGESELLSCHAFT (DE) 1978-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227412-A1 Substituted Benzimidazole Derivative And Use Thereof PPARD, PPARG, PPARA BACE1 226/4885ESR1 1330/4885ESR2 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.